Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Shengdia Pharmaceutical is a major biopharmaceutical subsidiary of Jiangsu Hengrui Pharmaceuticals, based in Suzhou, China. The company specializes in the discovery, development, and commercial-scale manufacturing of therapeutic biologics, with a strong emphasis on oncology and autoimmune diseases. Its portfolio includes the blockbuster PD-1 inhibitor Camrelizumab, which has received multiple approvals in China for various cancer indications. Suzhou Shengdia maintains state-of-the-art GMP manufacturing facilities and plays a critical role in advancing Hengrui's innovative biologics pipeline globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Suzhou Shendiab Pharmaceutical.